Form 4: Avidity Biosciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Avidity Biosciences' Chief Scientific and Technology Officer, W. Michael Flanagan, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• W. Michael Flanagan, the Chief Scientific and Technology Officer of Avidity Biosciences, exercised stock options to acquire 24,000 shares of common stock at a price of $22.47 per share on December 11, 2024.
• On the same day, Flanagan sold 24,000 shares of common stock at a weighted-average price of $35.7667 per share, with individual sales ranging from $35.37 to $36.46.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 12, 2024.
• Following these transactions, Flanagan directly owns 85,389 shares of common stock and 86,000 stock options.

Sentiment

Score: 5

Explanation: The document reflects a routine insider transaction under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine filing for insider transactions, and the use of a 10b5-1 plan is a common practice to avoid accusations of insider trading. It is typical for executives to exercise options and sell shares for personal financial management.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice among publicly traded companies to allow insiders to sell shares without the risk of insider trading allegations.
• The vesting schedule of the options, with monthly vesting over four years, is a common approach to incentivize long-term performance and retention of key personnel.
• The price range of the share sales, from $35.37 to $36.46, is within the typical range for market transactions of this type.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they represent a small portion of the total outstanding shares.
• The sale of shares by an executive may be perceived as a slight negative signal by some investors, but the use of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Avidity Biosciences, stock options, insider trading, Form 4, Rule 10b5-1, share sale, executive compensation, RNA